Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides
Marea Therapeutics has announced positive data from a Phase 2a clinical trial of MAR001, its lead candidate antibody targeting ANGPTL4. The trial demonstrated significant lipid-lowering effects in patients with elevated triglyceride levels:- MAR001 achieved up to 52.5% placebo-adjusted mean reduction in remnant cholesterol after 12 weeks of treatment[1][2]- The antibody also produced up to 52.7% placebo-adjusted mean reduction in triglycerides[1][2]- In a subgroup of patients with significantly elevated triglyceride levels (≥200 mg/dL), even stronger effects were observed, with up to 66% reduction in remnant cholesterol and 64% reduction in triglycerides[1][2]- The randomized, double-blind, placebo-controlled trial enrolled 55 participants with hypertriglyceridemia who received one of three doses (150mg, 300mg, or 450mg) or placebo every two weeks[2][5]- The highest dose groups demonstrated the strongest lipid-lowering effects[1]- MAR001 was generally well tolerated with no deaths, serious adverse events, or discontinuations due to adverse events reported[5]- Following these positive results, Marea Therapeutics plans to initiate a Phase 2b clinical trial imminently[1][2]- Marea Therapeutics emerged last year with $190 million in funding to advance its pipeline, which is led by MAR001[1]